Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding their holdings of Ordinary share American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details an increase in ADR holdings for specific directors and connected persons. These increases resulted from the re-investment of dividends paid to shareholders on July 7, 2011, at a price of $44.143 per ADR. No other material changes to the company's operations or financial position are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Transaction Date: July 7, 2011.
- Transaction Type: Dividend re-investment increasing ADR holdings.
- Price per ADR: $44.143.
- Directors Involved: Dr. M M Slaoui (296.002 ADRs), Mr. W C Louv (198.072 ADRs), and Dr. D Pulman (256.516 ADRs).
- Connected Person: Dr. K Slaoui (8.757 ADRs).
- Reporting Date: July 13, 2011.